Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients
Ibrutinib plus fludarabine/cyclophosphamide/rituximab (FCR) induces deep responses in previously untreated young patients with chronic lymphocytic leukemia (CLL), with 39% of evaluable patients achieving complete response with bone marrow minimal residual disease negativity (BM MRD-neg) and 89% achieving BM MRD-neg, significantly higher than the 20% rate seen historically with FCR alone.
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
In pooled data from 3 randomized studies, the benefit of ibrutinib on progression-free and overall survival is most marked in patients with CLL/SLL with del11q, which is not the case with ofatumumab, chlorambucil, or bendamustine/rituximab.
Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)
Progression-free survival for treatment-naive ibrutinib-treated chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) patients was similar regardless of age subgroup, whereas it was shorter for chlorambucil-treated patients aged ≥75 years compared with those aged 65 to
Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL
With a median time on study of 28.6 months, ibrutinib demonstrated an 88% reduction in risk of progression or death in an elderly chronic lymphocytic leukemia/small lymphocytic leukemia patient population, with treatment-limiting adverse events decreasing in frequency with longer follow-up.
After 5 years of follow-up, single-agent ibrutinib continues to show durable responses in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, including those with del17p, del11q, or unmutated IGVH.
A Diagnostic Test for Lupus Based on DNA Methylation Signatures from Peripheral Blood Mononuclear Cells
A definitive diagnosis of systemic lupus erythematosus (SLE) differentiating it from other rheumatic and autoimmune diseases can be challenging, because of a lack of definitive tests with sufficient sensitivity and specificity, as well as the absence of reliable biomarkers.
Pregnancy Complications in Lupus: Retrospective Observational Analysis from a US Health Claims Database
The Epidemiology of Systemic Lupus Erythematosus: Disease Prevalence and Impact on Employment and Work Productivity
Two important studies presented at the American College of Rheumatology annual meeting held in San Diego, California from October 25-30, 2013 analyzed the prevalence of systemic lupus erythematosus (SLE) and lupus nephritis in the US population, as well as the impact of SLE on employment and work productivity in American workers.
Effects of Blisibimod on Renal and Inflammation Biomarkers and on Serum Immunoglobulin and Infection Risk in Patients with Lupus: Results from the PEARL-SC and Open-Label Extension Studies
Blisibimod is a subcutaneously administered inhibitor of B-cell activating factor (BAFF) that has been evaluated in patients with systemic lupus erythematosus (SLE) in the phase 2b PEARL-SC trial and in an ensuing open-label extension study (NCT01305746).
Page 5 of 7
Results 41 - 50 of 61
Results 41 - 50 of 61